Dr. Brenda W. Cooper
Claim this profileCase Western Reserve University
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
11 reported clinical trials
30 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
CD33 positive
t(8;21) negative
inv(16) negative
2Acute Myeloid Leukemia
CD33 positive
t(8;21) negative
inv(16) negative
Affiliated Hospitals
Clinical Trials Brenda W. Cooper is currently running
DFP-10917
for Acute Myeloid Leukemia
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.
Recruiting2 awards Phase 34 criteria
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
More about Brenda W. Cooper
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Brenda W. Cooper has experience with
- Dexamethasone
- Cytarabine
- Ibrutinib
- VOR33
- Cyclophosphamide
- Allopurinol
Breakdown of trials Brenda W. Cooper has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Leukemia
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brenda W. Cooper specialize in?
Brenda W. Cooper focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved CD33 positive patients, or patients who are t(8;21) negative.
Is Brenda W. Cooper currently recruiting for clinical trials?
Yes, Brenda W. Cooper is currently recruiting for 3 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Brenda W. Cooper has studied deeply?
Yes, Brenda W. Cooper has studied treatments such as Dexamethasone, Cytarabine, Ibrutinib.
What is the best way to schedule an appointment with Brenda W. Cooper?
Apply for one of the trials that Brenda W. Cooper is conducting.
What is the office address of Brenda W. Cooper?
The office of Brenda W. Cooper is located at: Case Western Reserve University, Cleveland, Ohio 44106 United States. This is the address for their practice at the Case Western Reserve University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.